GlassScriptPhysician profile
David P York
NPI 1538205927
$756.61
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $135.64 | 2019 | |
| Glaxosmithkline, LLC. | $125.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $98.96 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $95.64 | 2019 | |
| Mylan Specialty L.P. | $46.78 | 2019-2020 | |
| Philips North America LLC | $35.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.01 | 2019 | |
| Gilead Sciences, INC. | $20.81 | 2019 | |
| Shire North American Group INC | $19.75 | 2019 | |
| Genzyme Corporation | $19.03 | 2019 | |
| Melinta Therapeutics, LLC | $18.87 | 2019 | |
| United Therapeutics Corporation | $18.77 | 2019 | |
| Circassia INC. | $17.03 | 2019 | |
| Merck Sharp & Dohme LLC | $16.13 | 2019 | |
| Phadia US INC. | $15.56 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.99 | 2020 | |
| Advanced Respiratory, INC | $14.83 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.81 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $8.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David York listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.